RIPOR2 Expression Decreased by HPV-16 E6 and E7 Oncoproteins: An Opportunity in the Search for Prognostic Biomarkers in Cervical Cancer

J. Omar Muñoz-Bello & Marcela Lizano et al. · 2022-12-06

9Citations

High-risk human papillomavirus (HPV) infection is the main risk factor for cervical cancer (CC) development, where the continuous expression of E6 and E7 oncoproteins maintain the malignant phenotype. In Mexico, around 70% of CC cases are diagnosed in advanced stages, impacting the survival of patients. The aim of this work was to identify biomarkers affected by HPV-16 E6 and E7 oncoproteins that impact the prognosis of CC patients. Expression profiles dependent on E6 and E7 oncoproteins, as well as their relationship with biological processes and cellular signaling pathways, were analyzed in CC cells. A comparison among expression profiles of E6- and E7-expressing cells and that from a CC cohort obtained from The Cancer Genome Atlas (TCGA) demonstrated that the expression of 13 genes impacts the overall survival (OS). A multivariate analysis revealed that the downregulated expression of RIPOR2 was strongly associated with a worse OS. RIPOR2, including its transcriptional variants, were overwhelmingly depleted in E6- and E7-expressing cells. Finally, in a Mexican cohort, it was found that in premalignant cervical lesions, RIPOR2 expression decreases as the lesions progress; meanwhile, decreased RIPOR2 expression was also associated with a worse OS in CC patients.

Journal
Cells
TL;DR

High-risk human papillomavirus infection is the main risk factor for cervical cancer development, where the continuous expression of E6 and E7 oncoproteins maintain the malignant phenotype, and expression of 13 genes impacts the overall survival (OS).

AI-generated by Semantic Scholar

Funding
National Autonomous University of Mexico Grant PAPIIT IN200219Consejo Nacional de Ciencia y Tecnología Grant PRONAII Virus y Cáncer 303044Consejo Nacional de Ciencia y Tecnología Grant PCC 320812Consejo Nacional de Ciencia y Tecnología Grant CF-2019-51488Programa de Apoyo en Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México PAPIIT-UNAM Grant IN200219Programa de Apoyo en Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México PAPIIT-UNAM Grant 017/007/IBIPrograma de Apoyo en Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México PAPIIT-UNAM Grant CEI/1144/17Programa de Apoyo en Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México PAPIIT-UNAM Grant 303044Programa de Apoyo en Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México PAPIIT-UNAM Grant 320812Programa de Apoyo en Proyectos de Investigación e Innovación Tecnológica, Universidad Nacional Autónoma de México PAPIIT-UNAM Grant CF-2019-51488Instituto Nacional de Cancerología Grant IN200219Instituto Nacional de Cancerología Grant 017/007/IBIInstituto Nacional de Cancerología Grant CEI/1144/17Instituto Nacional de Cancerología Grant 303044Instituto Nacional de Cancerología Grant 320812Instituto Nacional de Cancerología Grant CF-2019-51488Consejo Nacional de Ciencia y Tecnología Grant IN200219Consejo Nacional de Ciencia y Tecnología Grant 017/007/IBIConsejo Nacional de Ciencia y Tecnología Grant CEI/1144/17Consejo Nacional de Ciencia y Tecnología Grant 303044Consejo Nacional de Ciencia y Tecnología Grant 320812